Yazar "Alqahtani, Saleh A." için listeleme
-
Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
Alqahtani, Saleh A.; Yılmaz, Yusuf; El-Kassas, Mohamed; Alswat, Khalid; Sanai, Faisal; AlZahrani, May; Abaalkhail, Faisal; AlShaikh, Manal; Stepanova, Maria; Younossi, Zobair M. (Wiley, 2024)Patients with chronic liver disease (CLD) experience health-related quality of life (HRQoL) and patient-reported outcomes (PROs) impairments. We assessed and identified predictors of HRQoL and PROs in CLD patients from ... -
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease
Younossi, Zobair M.; Alqahtani, Saleh A.; Alswat, Khalid; Yılmaz, Yusuf; Keklikkıran, Çağlayan; Funuyet-Salas, Jesús; Romero-Gómez, Manuel; Fan, Jian-Gao; Zheng, Ming-Hua; El-Kassas, Mohamed; Castera, Laurent; Liu, Chun-Jen; Wai-Sun Wong, Vincent; Zelber-Sagi, Shira; Allen, Alina M.; Lam, Brian; Treeprasertsuk, Sombat; Hameed, Saeed; Takahashi, Hirokazu; Kawaguchi, Takumi; Schattenberg, Jörn M.; Duseja, Ajay; Newsome, Phil N.; Francque, Sven; Spearman, C. Wendy; Castellanos Fernández, Marlen I.; Burra, Patrizia; Roberts, Stuart K.; Chan, Wah-Kheong; Arrese, Marco; Silva, Marcelo; Rinella, Mary; Singal, Ashwani K.; Gordon, Stuart; Fuchs, Michael; Alkhouri, Naim; Cusi, Kenneth; Loomba, Rohit; Ranagan, Jane; Eskridge, Wayne; Kautz, Achim; Ong, Janus P.; Kugelmas, Marcelo; Eguchi, Yuichiro; Diago, Moises; Yu, Ming-Lung; Gerber, Lynn; Fornaresio, Lisa; Nader, Fatema; Henry, Linda; Racila, Andrei; Golabi, Pegah; Stepanova, Maria; Carrieri, Patrizia; Lazarus, Jeffrey V. (Elsevier, 2023)Background & Aims: Patients with fatty liver disease may experience stigma from the disease or comorbidities. In this crosssectional study, we aimed to understand stigma among patients with nonalcoholic fatty liver disease ... -
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Zhou, Xiao-Dong; Targher, Giovanni; Byrne, Christopher D.; Somers, Virend; Kim, Seung Up; Chahal, C. Anwar A.; Wong, Vincent Wai-Sun; Cai, Jingjing; Shapiro, Michael D.; Eslam, Mohammed; Steg, Philippe Gabriel; Sung, Ki-Chul; Misra, Anoop; Li, Jian-Jun; Brotons, Carlos; Huang, Yuli; Papatheodoridis, George V.; Sun, Aijun; Yılmaz, Yusuf; Chan, Wah Kheong; Huang, Hui; Mendez-Sanchez, Nahum; Alqahtani, Saleh A.; Cortez-Pinto, Helena; Lip, Gregory Y. H.; de Knegt, Robert J.; Ocama, Ponsiano; Romero-Gomez, Manuel; Fudim, Marat; Sebastiani, Giada; Son, Jang Won; Ryan, John D.; Ikonomidis, Ignatios; Treeprasertsuk, Sombat; Pastori, Daniele; Lupsor-Platon, Monica; Tilg, Herbert; Ghazinyan, Hasmik; Boursier, Jerome; Hamaguchi, Masahide; Nguyen, Mindie H.; Fan, Jian-Gao; Goh, George Boon-Bee; Al Mahtab, Mamun; Hamid, Saeed; Perera, Nilanka; (George, Jacob; Zheng, Ming-Hua (Springer, 2023)Background Fatty liver disease in the absence of excessive alcohol consumption is an increasingly common condition with a global prevalence of similar to 25-30% and is also associated with cardiovascular disease (CVD). ... -
Knowledge about metabolic dysfunction-associated steatotic liver disease among the medical professionals from countries in the MENA region
Alqahtani, Saleh A.; Yılmaz, Yusuf; El-Kassas, Mohamed; Alswat, Khalid; Mawardi, Mohamed; Sanai, Faisal M.; Abaakhail, Faisal; Alghamdi, Saad; Al-Hamoudi, Waleed K; Nader, Fatema; Younossi, Zobair M. (Elsevier, 2024)Introduction and Objectives: Given the substantial burden of metabolic dysfunction-associated steatotic liver disease (MASLD), there is an urgent need to assess knowledge and awareness levels among physicians. We assessed ... -
Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa
Younossi, Zobair M.; Golabi, Pegah; Paik, James; Owrangi, Soroor; Yılmaz, Yusuf; El-Kassas, Mohamed; Alswat, Khalid; Alqahtani, Saleh A. (Wiley, 2024)Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is common and closely associated with type 2 diabetes (T2D). We assessed ... -
Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice
Lazarus, Jeffrey V.; Castera, Laurent; Mark, Henry E.; Allen, Alina M.; Adams, Leon A.; Anstee, Quentin M.; Arrese, Marco; Alqahtani, Saleh A.; Bugianesi, Elisabetta; Colombo, Massimo; Cusi, Kenneth; Hagström, Hannes; Loomba, Rohit; Romero-Gomez, Manuel; Schattenberg, Jörn M.; Thiele, Maja; Valenti, Luca; Wai-Sun Wong, Vincent; Yılmaz, Yusuf; Younossi, Zobair M.; Francque, Sven M.; Tsochatzis, Emmanuel A. (Elsevier, 2022)Background & Aims: Non-invasive tests (NITs) offer a practical solution for advanced fibrosis identification in non-alcoholic fatty liver disease (NAFLD). Despite increasing implementation, their use is not standardised, ...
